ANZCTR search results

This project will deliver innovative resilience training for older Australians (50+ years). Fifty years of age reflects a point of major work and life transition (National Seniors Australia) and we seek to assist adjustment at this critical life-stage. According to Beyond Blue and government reports, incidences of depression and stress are reported by 10-15% of the population over 50 years of age (Commonwealth Department of Health), with physical and psychological illness ranked the 2nd most common reason for people leaving the workforce prematurely (ABS, 2017). Our project is designed to mitigate these effects by improving psychological resilience among older Australians to keep them in the workforce longer, and to improve psychological outcomes and enhance community engagement among older unemployed Australians. Unlike conventional resilience training that takes a ‘one size fits all’ approach, we have developed a personalised self-reflection strategy to building resilience. This strategy enables participants to identify and build on their individual strengths, and to harness these in the face of challenges. Leveraging our success in fostering resilience in the Australian military, we will tailor our unique approach for older Australians and test its efficacy with two key groups; working and unemployed and retired older adults. This will be the first resilience training tailored to older adults with the objective of preventing mental illness and developing the skills and insights needed to cope with the inevitable adjustments and challenges of ageing. In collaboration with a major national employer and local councils, we will deliver a new tool to support older Australians to lead active and fulfilling lives, while reducing the risk of mental illness that affects Australians over 50.

This feasibility study is aiming to test a mobile phone app (called ‘SunVisor’) to determine its effectiveness, particularly in organ transplant recipients. Who is it for? You may be eligible for this study if you are aged 15 or older, are attending the Australian Transplant Games 2018 and have a mobile phone with internet access. Study details All participants will complete a baseline survey, download and install the SunVisor application and receive a tube of sunscreen. Throughout the period of the Transplant Games, participants will use the application at their discretion. After two weeks participants will partake in a 20 minute telephone interview about their experience using the application. It is hoped this research will show this app improves sun protection strategies and reduces sunburn incidence in this vulnerable population.

This parallel group, blinded, placebo-controlled randomised trial will determine whether 1500mg/day of metformin administered for 6 months improves walking ability in PAD patients. Based on sample size calculations focused on the minimal clinically important difference, 250 PAD patients that do not have diabetes, renal or cardiac failure will be included. The trial will employ an independently run minimisation randomisation system and identical appearance, weight and packaging of drug and placebo to ensure blinding of investigations, patients and assessors, along with balancing of important determinants of outcome. The primary outcome measure will be the 6-month maximum walking distance during a six minute walk test. Secondary outcomes will include physical activity assessed over 7 days with an accelerometer, health-related quality of life, leg blood supply assessed with ankle-brachial pressure index and circulating concentrations of key markers of angiogenesis. Adverse events will be monitored by an independent data monitoring committee. Previous trials indicate metformin is safe for patients without diabetes.

The study aims to evaluate the combined effect of a cognitive rehabilitation group (CRG) with intake of Queen Garnet plum (QGP) juice, to optimise cognition in adults with mild cognitive impairment (MCI). Biomedical measures would contribute to an understanding of the mechanisms of action associated with cognitive improvements. The study would include an 8week, doubleblind randomised controlled trial with two arms, CRG plus placebo, and CRG plus 250mL QGP juice, using MCI patients referred to the ISLHD Geriatric Outpatient Services or Rehabilitation and Medical Psychology Department. Recruitment and research consent of participants will occur within ISLHD clinics, with an aim of 72 subjects. Participants will attend a data collection session at baseline, conducted by Clinical Neuropsychologist and a Research Assistant, where participants will undergo the neuropsychological test battery, collection of demographic data, a food frequency questionnaire and instructions for a 4day food record, and blood collection. Subjects will be provided a 24hour Blood Pressure monitoring device, a urine and faecal sample collection kit, and their supplement/placebo to commence. These assessment procedures will be repeated at 8 weeks.

The objective of this study was to determine the effect of age, prolonged bypass and deep hypothermia on perioperative levels of cefazolin in children undergoing cardiac surgery.

The primary goal of this study is to determine the effects of two drug combinations (known as AD047 and AD282) on sleep apnoea severity (the apnoea/hypopnoea index) compared to a placebo (sugar pill). Other measures of sleep apnoea severity, upper airway function, breathing and symptoms will also be assessed as secondary outcomes.

Congenital aortic stenosis is a lifelong disease often requiring multiple interventions. Valvuloplasty refers to the procedure by which the valve obstruction is relieved by either incising the valve during a surgical procedure or utilising balloon to stretch the valve during an interventional cardiology procedure. We are seeking to determine the early and late outcomes of surgical or balloon aortic valvuloplasty and whether the technique use, influences the long term risk of re-intervention, other morbidities, or death.

The study investigates the absorption characteristics and safety of Medlab’s NanoCelle D3 (Vitamin D3 as cholecalciferol) administered to 8 healthy individuals. The dose to be administered in 10 sprays/5000 I.U./1.5mL. A total of four 10 mL blood samples will be collected from each participant at 0, 60, 180 and 360 minutes. The total study duration per participant is approximately 7.5 hours.

As many as 1 in 4 Australians experience chronic pain. There is a critical need for the development and evaluation of fast-acting non-pharmaceutical treatments that have the capacity to target the multidimensional nature of chronic pain. This study will compare the effects and mechanisms of mindfulness meditation against placebo and no-treatment control groups. Results will ultimately lead to targeted interventions that more effectively engage cognitive mechanisms associated with pain attenuation.

A double-blind (allocation concealed) randomised controlled trial conducted among Indigenous mother-infant pairs in the Northern Territory. To determine whether weekly vitamin D supplementation (compared to placebo) given to mothers (between 28 to 34 weeks gestation (inclusive) until birth) and their infants (birth until age 4 months) reduces the incidence of acute respiratory infection (hospitalisations or primary care presentations) in the infants first 12 months of life.